Figure S11 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma

Larissa Anastácio da Costa Carvalho; Nataliya Tovbis Shifrin; Manali S. Phadke; Michael F. Emmons; Ximo Pechuan-Jorge; Felix Mbuga; Oscar E. Ospina; Christopher Chow; Lillian Seu; Olivia L. Rose; Aparna Madhukeshwar Hegde; Nikhil I. Khushalani; Elsa Quintana; Keiran S.M. Smalley

doi:10.1158/2326-6066.31028336

Figure S11 from RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma

2026 Open access

Read full text

Authors: Larissa Anastácio da Costa Carvalho, Nataliya Tovbis Shifrin, Manali S. Phadke, Michael F. Emmons, Ximo Pechuan-Jorge, Felix Mbuga, Oscar E. Ospina, Christopher Chow, Lillian Seu, Olivia L. Rose, Aparna Madhukeshwar Hegde, Nikhil I. Khushalani

+2 more

Elsa Quintana, Keiran S.M. Smalley

DOI: 10.1158/2326-6066.31028336

Cited by: 0

Abstract

Supplemental Figure 11: CXCL signaling is altered in the presence of RMC-7977. (A) Heatmap showing the sources and receivers of CXCL signaling in the control, anti-PD1, RMC-7977 and anti-PD1 + RMC-7977 groups. (B) Violin plot showing the expression distribution of CXCL signaling ligands and receptors in the anti-PD1, RMC-7977 and anti-PD1 + RMC-7977 groups compared to control. Red represents the control and blue the indicated treated group.

Fields of Study & Subjects

Melanoma and MAPK Pathways Cutaneous Melanoma Detection and Management Chemokine receptors and signaling

Publication details

Publication date: 8 January 2026